首页 > 市场调查报告书 > 製药

感染疾病

市场调查报告书

商品编码

1574950

胜肽抗生素市场，按产品类型、疾病、给药途径、国家和地区 - 2024-2032 年行业分析、市场规模、市场份额和预测

Peptide Antibiotics Market, By Product Type, By Disease, By Route of Administration, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日期: 2024年10月02日 | 出版商:

AnalystView Market Insights | 英文 260 Pages | 商品交期: 2-3个工作天内

价格

简介目录

报告要点

2023年，胜肽类抗生素市场规模为48.0409亿美元，2024年至2032年复合年增长率为11.20%。

多肽抗生素市场-市场动态

抗生素抗药性的增加推动了对胜肽抗生素创新的需求。

抗生素抗药性的上升是一个大问题，增加了对肽类抗生素的需求。根据美国疾病管制与预防中心 (CDC) 的数据，美国每年有超过 280 万例抗生素抗药性感染，导致超过 35,000 人死亡。这是一个严重的问题，显示我们需要新的治疗方法，因为许多常见的抗生素不再有效。

胜肽抗生素可能是个很好的解决方案。它们的作用与普通抗生素不同，研究人员正在研究它们的特殊功能以对抗抗生素抗药性。这些独特的特性使胜肽抗生素能够有效对抗抗药性细菌，让我们希望找到更好的方法来控制感染。

肽类抗生素市场-关键见解

根据我们的研究分析师分享的分析，预计全球市场在预测期内（2024-2032 年）每年将以 11.20% 左右的复合年增长率成长

根据产品类型细分，预计核醣体合成胜肽抗生素将在 2023 年呈现最大市场份额

按疾病细分，2023年皮肤感染为主导类型

根据给药途径细分，注射剂是 2023 年的主导类型

按地区划分，北美是 2023 年的主要收入来源

胜肽抗生素市场-細項分析：

全球胜肽抗生素市场根据产品类型、疾病、给药途径和地区进行细分。

根据产品类型，市场分为两类：核醣体合成胜肽抗生素和非核醣体合成胜肽抗生素。核醣体合成胜肽抗生素是最突出的部分。这主要是因为它们可以很好地抵抗各种感染，尤其是由革兰氏阳性菌引起的感染。它们通常更容易口服，这使得患者更有可能接受治疗。随着抗生素抗药性细菌的兴起，人们对这些抗生素进行了更多的研究，从而产生了新的有效选择。它们治疗严重感染的能力使它们成为市场的关键部分，使医生和患者受益。

市场依疾病分为两类：皮肤感染、HABP/VABP、血流感染和其他。皮肤感染部分最为突出。皮肤感染很常见，可由多种细菌引起，因此有效的治疗至关重要。胜肽抗生素被经常使用，因为它们可以有效地针对这些细菌。由于皮肤感染很普遍，如果不及时治疗可能会导致更严重的併发症，因此对这些抗生素的需求强劲。这种对治疗皮肤感染的关注有助于推动市场成长，并为医疗保健提供者和患者提供支援。

多肽抗生素市场-地理洞察

北美的胜肽类抗生素市场正在快速成长。这一增长是由于对抗抗药性细菌的新型抗生素的需求不断增加。许多医院和医疗保健提供者正在寻找有效的治疗方法。该领域的研究和开发正在获得更多资金，这有助于创造新的胜肽抗生素。

此外，医生和患者对这些治疗方法益处的认识正在传播。该市场也得到鼓励创新的监管框架的支持。总体而言，北美正在成为胜肽抗生素产业的关键参与者。

多胜肽抗生素市场-竞争格局：

胜肽抗生素市场竞争激烈，百特国际、诺华和默克等主要参与者处于领先地位。这些公司专注于开发新型有效的抗生素来应对日益增长的抗药性。阿斯特捷利康（AstraZeneca）和勃林格殷格翰（Boehringer Ingelheim）等其他公司也投资研究以创新和改进其产品。 Sandoz 和 Hikma Pharmaceuticals 专注于仿製药，使治疗更容易获得。同时，安进和吉利德科学专注于独特的疗法，以满足特定的医疗需求。总体而言，这些公司正在努力透过合作、研究和扩大产品线来增强自己的地位，以应对全球健康挑战。

介绍
- 按地理位置分類的细分市场占有率分析
北美洲
- 概述
- 北美肽类抗生素主要製造商
- 北美市场规模和预测（按国家）
- 北美市场规模和预测（按产品类型）
- 北美市场规模与预测（按疾病）
- 北美市场规模与预测（按管理途径）
- 我们
- 加拿大
欧洲
- 概述
- 欧洲胜肽类抗生素主要製造商
- 欧洲市场规模和预测（按国家）
- 欧洲市场规模和预测（按产品类型）
- 欧洲市场规模与预测（按疾病）
- 欧洲市场规模与预测（按管理途径）
- 德国
- 义大利
- 英国
- 法国
- 俄罗斯
- 荷兰
- 瑞典
- 波兰
- 欧洲其他地区
亚太地区 (APAC)
- 概述
- 亚太地区胜肽类抗生素主要製造商
- 亚太地区市场规模与预测（按国家）
- 亚太地区市场规模与预测（依产品类型）
- 亚太地区市场规模与预测（按疾病）
- 亚太地区市场规模与预测（依管理途径）
- 印度
- 中国
- 日本
- 韩国
- 澳洲
- 泰国
- 印尼
- 菲律宾
- 亚太地区其他地区
拉丁美洲
- 概述
- 拉丁美洲肽类抗生素主要製造商
- 拉丁美洲市场规模与预测（按国家）
- 拉丁美洲市场规模与预测（按产品类型）
- 拉丁美洲市场规模与预测（按疾病）
- 拉丁美洲市场规模与预测（按管理途径）
- 巴西
- 墨西哥
- 阿根廷
- 哥伦比亚
- 拉丁美洲其他地区
中东和非洲
- 概述
- 中东和非洲胜肽类抗生素主要製造商
- 中东和非洲市场规模及预测（按国家）
- 中东和非洲市场规模及预测（按产品类型）
- 中东和非洲市场规模及预测（按疾病）
- 中东和非洲市场规模及预测（按管理途径）
- 沙乌地阿拉伯
- 阿拉伯聯合大公国
- 以色列
- 土耳其
- 阿尔及利亚
- 埃及
- MEA 的其余部分

第 11 章：主要供应商分析-胜肽抗生素产业

竞争仪表板
公司简介
- Baxter International Inc.
- Novartis AG
- Merck & Co., Inc.
- AstraZeneca PLC
- Boehringer Ingelheim GmbH
- Fujifilm Diosynth Biotechnologies
- Hikma Pharmaceuticals PLC
- Polymun Scientific GmbH
- Sandoz International GmbH (a Novartis division)
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Amgen Inc.
- Gilead Sciences, Inc.
- Hoffmann-La Roche Ltd.
- Vitae Pharmaceuticals, Inc.
- Thermo Fisher Scientific Inc.
- CureVac AG

第 12 章：360 度分析师视角

第 13 章：附录

研究方法
参考
缩写
免责声明
联络我们

简介目录

Product Code: ANV3953

REPORT HIGHLIGHT

Peptide Antibiotics Market size was valued at USD 4,804.09 Million in 2023, expanding at a CAGR of 11.20% from 2024 to 2032.

The peptide antibiotics market involves the development and sale of antibiotics made from small proteins called peptides. These antibiotics are effective against bacteria and can help treat infections, especially those resistant to traditional antibiotics. The market is growing due to increasing bacterial resistance and the need for new treatments. Researchers are exploring different peptides to find new drugs that are safe and effective. This area of medicine is important for public health as it offers hope in the fight against stubborn infections. Overall, peptide antibiotics represent a promising solution in the battle against antibiotic resistance.

Peptide Antibiotics Market- Market Dynamics

Increasing antibiotic resistance drives demand for peptide antibiotics innovation.

The rise of antibiotic resistance is a big problem that is increasing the demand for peptide antibiotics. According to the Centers for Disease Control and Prevention (CDC), there are more than 2.8 million antibiotic-resistant infections in the U.S. every year, leading to over 35,000 deaths. This is a serious issue and shows we need new treatments because many common antibiotics no longer work well.

Peptide antibiotics could be a good solution. They work differently than regular antibiotics, and researchers are looking into their special features to fight antibiotic resistance. These unique properties make peptide antibiotics effective against resistant bacteria, giving us hope for better ways to control infections.

Peptide Antibiotics Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 11.20% over the forecast period (2024-2032)

Based on product type segmentation, Ribosomal Synthesized Peptide Antibiotics was predicted to show maximum market share in the year 2023

Based on Disease segmentation, Skin Infection was the leading type in 2023

Based on Route of Administration segmentation, Injectables was the leading type in 2023

based on Region, North America was the leading revenue generator in 2023

Peptide Antibiotics Market- Segmentation Analysis:

The Global Peptide Antibiotics Market is segmented based on Product Type, Disease, Route of Administration, and Region.

The market is divided into two categories based on Product Type: Ribosomal Synthesized Peptide Antibiotics, and Non-Ribosomal Synthesized Peptide Antibiotics. Ribosomal Synthesized Peptide Antibiotics are the most prominent segment. This is mainly because they work well against various infections, especially those caused by Gram-positive bacteria. They are often easier to take by mouth, which makes patients more likely to follow their treatment. With the rise of antibiotic-resistant bacteria, more research is being done on these antibiotics, leading to new and effective options. Their ability to treat serious infections makes them a key part of the market, benefiting both doctors and patients.

The market is divided into two categories based on Disease: Skin Infection, HABP/VABP, Blood Stream Infection, and Others. The skin infection segment is the most prominent. Skin infections are common and can be caused by a variety of bacteria, making effective treatments essential. Peptide antibiotics are frequently used because they effectively target these bacteria. Since skin infections are widespread and can lead to more serious complications if left untreated, there is a strong demand for these antibiotics. This focus on treating skin infections helps drive growth in the market and supports both healthcare providers and patients.

Peptide Antibiotics Market- Geographical Insights

The peptide antibiotics market in North America is growing rapidly. This rise is due to the increasing need for new antibiotics to fight drug-resistant bacteria. Many hospitals and healthcare providers are looking for effective treatments. Research and development in this area are getting more funding, which helps create new peptide antibiotics.

Moreover, awareness of the benefits of these treatments is spreading among doctors and patients. The market is also supported by regulatory frameworks that encourage innovation. Overall, North America is becoming a key player in the peptide antibiotics industry.

Peptide Antibiotics Market- Competitive Landscape:

The peptide antibiotics market is highly competitive, with key players like Baxter International, Novartis, and Merck leading the way. These companies focus on developing new and effective antibiotics to tackle rising resistance. Others, like AstraZeneca and Boehringer Ingelheim, also invest in research to innovate and improve their product offerings. Sandoz and Hikma Pharmaceuticals specialize in generics, making treatments more accessible. Meanwhile, Amgen and Gilead Sciences focus on unique therapies to meet specific medical needs. Overall, these companies are striving to enhance their positions through collaboration, research, and expanding their product lines to address global health challenges.

Recent Developments:

In September 2024, Agilent Technologies Inc. finalized its acquisition of BIOVECTRA, a Canadian contract development and manufacturing organization (CDMO) that focuses on biologics, highly potent active pharmaceutical ingredients, and other compounds for targeted therapies.

In August 2024, Bora Pharmaceuticals Co., Ltd. strategically invested in Tanvex Biopharma Co., Ltd. As part of this partnership, Bora Biologics, a subsidiary of Bora that specializes in large molecule CDMO, will merge its biomanufacturing facilities with Tanvex to establish a global service for the development and supply of biologics.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL PEPTIDE ANTIBIOTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Baxter International Inc.
Novartis AG
Merck & Co., Inc.
AstraZeneca PLC
Boehringer Ingelheim GmbH
Fujifilm Diosynth Biotechnologies
Hikma Pharmaceuticals PLC
Polymun Scientific GmbH
Sandoz International GmbH (a Novartis division)
Bristol-Myers Squibb Company
Eli Lilly and Company
Amgen Inc.
Gilead Sciences, Inc.
Hoffmann-La Roche Ltd.
Vitae Pharmaceuticals, Inc.
Thermo Fisher Scientific Inc.
CureVac AG

GLOBAL PEPTIDE ANTIBIOTICS MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032

Ribosomal Synthesized Peptide Antibiotics
Non-Ribosomal Synthesized Peptide Antibiotics

GLOBAL PEPTIDE ANTIBIOTICS MARKET, BY DISEASE- MARKET ANALYSIS, 2019 - 2032

Skin Infection
HABP/VABP
Blood Stream Infection
Others

GLOBAL PEPTIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

Oral
Injectable
Topical
Others

GLOBAL PEPTIDE ANTIBIOTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Peptide Antibiotics Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Peptide Antibiotics Market Snippet by Product Type
- 2.1.2. Peptide Antibiotics Market Snippet by Disease
- 2.1.3. Peptide Antibiotics Market Snippet by Route of Administration
- 2.1.4. Peptide Antibiotics Market Snippet by Country
- 2.1.5. Peptide Antibiotics Market Snippet by Region
2.2. Competitive Insights

3. Peptide Antibiotics Key Market Trends

3.1. Peptide Antibiotics Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Peptide Antibiotics Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Peptide Antibiotics Market Opportunities
3.4. Peptide Antibiotics Market Future Trends

4. Peptide Antibiotics Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Peptide Antibiotics Market: COVID-19 Impact Analysis

5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
- 5.2.1. Top Performing Segments
- 5.2.2. Marginal Growth Segments
- 5.2.3. Top Looser Segments
- 5.2.4. Marginal Loss Segments

6. Peptide Antibiotics Market Landscape

6.1. Peptide Antibiotics Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Peptide Antibiotics Market - By Product Type

7.1. Overview
- 7.1.1. Segment Share Analysis, By Product Type, 2023 & 2032 (%)
- 7.1.2. Ribosomal Synthesized Peptide Antibiotics
- 7.1.3. Non-Ribosomal Synthesized Peptide Antibiotics

8. Peptide Antibiotics Market - By Disease

8.1. Overview
- 8.1.1. Segment Share Analysis, By Disease, 2023 & 2032 (%)
- 8.1.2. Skin Infection
- 8.1.3. HABP/VABP
- 8.1.4. Blood Stream Infection
- 8.1.5. Others

9. Peptide Antibiotics Market - By Route of Administration

9.1. Overview
- 9.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
- 9.1.2. Oral
- 9.1.3. Injectable
- 9.1.4. Topical
- 9.1.5. Others

10. Peptide Antibiotics Market- By Geography

10.1. Introduction
- 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
10.2. North America
- 10.2.1. Overview
- 10.2.2. Peptide Antibiotics Key Manufacturers in North America
- 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.2.4. North America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 10.2.5. North America Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.2.7. U.S.
  - 10.2.7.1. Overview
  - 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.2.7.3. U.S. Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 10.2.7.4. U.S. Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.2.7.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.2.8. Canada
  - 10.2.8.1. Overview
  - 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.2.8.3. Canada Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 10.2.8.4. Canada Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.2.8.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.3. Europe
- 10.3.1. Overview
- 10.3.2. Peptide Antibiotics Key Manufacturers in Europe
- 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.3.4. Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 10.3.5. Europe Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.3.7. Germany
  - 10.3.7.1. Overview
  - 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.7.3. Germany Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 10.3.7.4. Germany Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.3.7.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.3.8. Italy
  - 10.3.8.1. Overview
  - 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.8.3. Italy Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 10.3.8.4. Italy Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.3.8.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.3.9. United Kingdom
  - 10.3.9.1. Overview
  - 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.9.3. United Kingdom Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 10.3.9.4. United Kingdom Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.3.9.5. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.3.10. France
  - 10.3.10.1. Overview
  - 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.10.3. France Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 10.3.10.4. France Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.3.10.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.3.11. Russia
  - 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.11.2. Russia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 10.3.11.3. Russia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.3.11.4. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.3.12. Netherlands
  - 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.12.2. Netherlands Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 10.3.12.3. Netherlands Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.3.12.4. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.3.13. Sweden
  - 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.13.2. Sweden Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 10.3.13.3. Sweden Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.3.13.4. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.3.14. Poland
  - 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.14.2. Poland Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 10.3.14.3. Poland Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.3.14.4. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.3.15. Rest of Europe
  - 10.3.15.1. Overview
  - 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.15.3. Rest of the Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 10.3.15.4. Rest of the Europe Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.3.15.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.4. Asia Pacific (APAC)
- 10.4.1. Overview
- 10.4.2. Peptide Antibiotics Key Manufacturers in Asia Pacific
- 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.4.4. Asia Pacific Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 10.4.5. Asia Pacific Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.4.6. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.4.7. India
  - 10.4.7.1. Overview
  - 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.7.3. India Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 10.4.7.4. India Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.4.7.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.4.8. China
  - 10.4.8.1. Overview
  - 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.8.3. China Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 10.4.8.4. China Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.4.8.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.4.9. Japan
  - 10.4.9.1. Overview
  - 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.9.3. Japan Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 10.4.9.4. Japan Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.4.9.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.4.10. South Korea
  - 10.4.10.1. Overview
  - 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.10.3. South Korea Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 10.4.10.4. South Korea Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.4.10.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.4.11. Australia
  - 10.4.11.1. Overview
  - 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.11.3. Australia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 10.4.11.4. Australia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.4.11.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.4.12. Thailand
  - 10.4.12.1. Overview
  - 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.12.3. Thailand Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 10.4.12.4. Thailand Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.4.12.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.4.13. Indonesia
  - 10.4.13.1. Overview
  - 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.13.3. Indonesia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 10.4.13.4. Indonesia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.4.13.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.4.14. Philippines
  - 10.4.14.1. Overview
  - 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.14.3. Philippines Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 10.4.14.4. Philippines Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.4.14.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.4.15. Rest of APAC
  - 10.4.15.1. Overview
  - 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.15.3. Rest of APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 10.4.15.4. Rest of APAC Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.4.15.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.5. Latin America
- 10.5.1. Overview
- 10.5.2. Peptide Antibiotics Key Manufacturers in Latin America
- 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.5.4. Latin America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 10.5.5. Latin America Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.5.6. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.5.7. Brazil
  - 10.5.7.1. Overview
  - 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.7.3. Brazil Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 10.5.7.4. Brazil Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.5.7.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.5.8. Mexico
  - 10.5.8.1. Overview
  - 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.8.3. Mexico Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 10.5.8.4. Mexico Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.5.8.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.5.9. Argentina
  - 10.5.9.1. Overview
  - 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.9.3. Argentina Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 10.5.9.4. Argentina Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.5.9.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.5.10. Colombia
  - 10.5.10.1. Overview
  - 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.10.3. Colombia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 10.5.10.4. Colombia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.5.10.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.5.11. Rest of LATAM
  - 10.5.11.1. Overview
  - 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.11.3. Rest of LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 10.5.11.4. Rest of LATAM Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.5.11.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.6. Middle East and Africa
- 10.6.1. Overview
- 10.6.2. Peptide Antibiotics Key Manufacturers in Middle East and Africa
- 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.6.4. Middle East and Africa Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 10.6.5. Middle East and Africa Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.6.7. Saudi Arabia
  - 10.6.7.1. Overview
  - 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.7.3. Saudi Arabia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 10.6.7.4. Saudi Arabia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.6.7.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.6.8. United Arab Emirates
  - 10.6.8.1. Overview
  - 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.8.3. United Arab Emirates Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 10.6.8.4. United Arab Emirates Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.6.8.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.6.9. Israel
  - 10.6.9.1. Overview
  - 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.9.3. Israel Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 10.6.9.4. Israel Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.6.9.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.6.10. Turkey
  - 10.6.10.1. Overview
  - 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.10.3. Turkey Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 10.6.10.4. Turkey Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.6.10.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.6.11. Algeria
  - 10.6.11.1. Overview
  - 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.11.3. Algeria Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 10.6.11.4. Algeria Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.6.11.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.6.12. Egypt
  - 10.6.12.1. Overview
  - 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.12.3. Egypt Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 10.6.12.4. Egypt Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.6.12.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.6.13. Rest of MEA
  - 10.6.13.1. Overview
  - 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.13.3. Rest of MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 10.6.13.4. Rest of MEA Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.6.13.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Peptide Antibiotics Industry

11.1. Competitive Dashboard
11.2. Company Profiles
- 11.2.1. Baxter International Inc.
- 11.2.2. Novartis AG
- 11.2.3. Merck & Co., Inc.
- 11.2.4. AstraZeneca PLC
- 11.2.5. Boehringer Ingelheim GmbH
- 11.2.6. Fujifilm Diosynth Biotechnologies
- 11.2.7. Hikma Pharmaceuticals PLC
- 11.2.8. Polymun Scientific GmbH
- 11.2.9. Sandoz International GmbH (a Novartis division)
- 11.2.10. Bristol-Myers Squibb Company
- 11.2.11. Eli Lilly and Company
- 11.2.12. Amgen Inc.
- 11.2.13. Gilead Sciences, Inc.
- 11.2.14. Hoffmann-La Roche Ltd.
- 11.2.15. Vitae Pharmaceuticals, Inc.
- 11.2.16. Thermo Fisher Scientific Inc.
- 11.2.17. CureVac AG